Article
Impact of prophylactic skin toxicity management on treatment continuity and clinical outcomes in EGFR-mutant non-small cell lung cancer treated with osimertinib: a 7-year real-world retrospective cohort study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer - 13 Jun 2026
Khongyot T, Melgo M N B, Nurat R, Chanthachot M, Kochasen R, Homkaen W, Longakit R Z, Sunphakorn C, Detkaew N, Biswas M, Srikaew P, Dejrattanawichai S, Majam T
Abstract excerpt
INTRODUCTION: Osimertinib is the preferred epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for patients with EGFR-mutant non-small cell lung cancer (NSCLC) due to its superior efficacy and favorable safety profile. Nevertheless, dermatologic toxicities remain common and may disrupt treatment continuity, underscoring the importance of effective supportive care. Evidence regarding the clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.